Vascular Endothelial Growth Factor (e.g., Vegf-a, Vegf-b, Etc.) Or Derivative Patents (Class 514/8.1)
-
Patent number: 8476231Abstract: Novel products comprising conditioned cell culture medium compositions and methods of use are described. The conditioned cell medium compositions of the invention may be comprised of any known defined or undefined medium and may be conditioned using any eukaryotic cell type. Once the cell medium of the invention is conditioned, it may be used in any state. Physical embodiments of the conditioned medium include, but are not limited to, liquid or solid, frozen, lyophilized or dried into a powder. Additionally, the medium is formulated with a pharmaceutically acceptable carrier as a vehicle for internal administration, applied directly to a food item or product, or formulated with a salve or ointment for topical applications. Also, the medium may be further processed to concentrate or reduce one or more factors or components contained within the medium.Type: GrantFiled: March 9, 2012Date of Patent: July 2, 2013Assignee: Allergan, Inc.Inventors: Gail K. Naughton, David L. Horwitz, Mark A. Applegate, Joan Zeltinger, Jonathan N. Mansbridge, Andreas Kern, Lee K. Landeen, Anthony Ratcliffe, R. Emmett Pinney
-
Publication number: 20130164303Abstract: The present invention relates to pharmaceutical compositions for a combination therapy with a cytokine antagonist and a corticosteroid. By means of the combination therapy diseases such as osteoarthritis, tendon injuries and/or degenerative spinal diseases can be treated.Type: ApplicationFiled: November 7, 2011Publication date: June 27, 2013Applicant: Orthogen AGInventors: Peter Wehling, Julio Reinecke
-
Publication number: 20130156692Abstract: The present application provides biligand and triligand protein-catalyzed capture (PCC) agents that specifically bind VEGF, as well as the use of these capture agents as detection, diagnosis, and treatment agents.Type: ApplicationFiled: August 31, 2012Publication date: June 20, 2013Applicant: Integrated Diagnostics, Inc.Inventors: Suresh Mark Pitram, Heather Dawn Agnew, Tsun Yin Lai, Rosemary Dyane Rohde, Paul Edward Kearney
-
Publication number: 20130150285Abstract: Therapeutic and cosmetic uses and applications of calreticulin are provided. In particular, the invention relates to therapeutic and cosmetic uses and applications of calreticulin to a patient in need of such treatment including in tissue repair, wound healing, ulcers, reducing scar formation, and reducing or eliminating wrinkles.Type: ApplicationFiled: June 17, 2011Publication date: June 13, 2013Applicants: CALREGEN INC., NEW YORK UNIVERSITYInventors: Leslie I. Gold, Marek Michalak
-
Publication number: 20130149318Abstract: A PEG based hydrogel and a procedure for its topical application to the surface of the pia mater of the spinal cord that can be used for intrathecal delivery of diverse drug and biomolecular therapies for the treatment of traumatic central nervous system injuries and disorders including spinal cord injury (SCI), multiple sclerosis (MS) and amyotrophic lateral sclerosis (ALS) are provided. This “painting of the pia” with biofunctionalized hydrogel material may be used as a prelude strategy in the therapeutic management of these CNS disorders. The strategy may be designed to create a microenvironment within the damaged regions of the spinal cord that is more conducive to the successful application of subsequent regeneration based treatments such as cell replacement therapies or endogenous regeneration and plasticity stimulation via application of growth factors or gene therapy.Type: ApplicationFiled: December 13, 2012Publication date: June 13, 2013Applicant: INVIVO THERAPEUTICS CORPORATIONInventor: InVivo Therapeutics Corporation
-
Patent number: 8461109Abstract: The invention also relates to a method for of enhancing the acceptance and/or healing of a skin graft in a subject comprising stimulating angiogenesis and lymphangiogenesis with an effective amount of an isolated VEGF-D polypeptide.Type: GrantFiled: April 17, 2012Date of Patent: June 11, 2013Assignee: Vegenics Pty LimitedInventors: Marc G. Achen, Steven Alan Stacker, Kari Alitalo
-
Publication number: 20130143807Abstract: Disclosed herein are heretofore undescribed preparations of highly concentrated, solubilized proteins, such as but not limited to, Bone Morphogenetic Proteins. Such protein preparations can be formulated in an aqueous carrier at protein concentrations in excess of 10 mg/ml when using the methods of manufacture taught herein. Such methods yield stable protein preparations in either solubilized or lyophilized form. The protein preparations of the present invention are particularly beneficial when administered either locally or systemically, in part, because low administration volumes can be accomplished. This is especially important for local treatment of certain anatomic locations such as, for example, the synovial fluid of a joint when treating osteoarthritis with BMP-7 or the intradiscal space when treating degenerative disc disease with BMP-7.Type: ApplicationFiled: June 7, 2012Publication date: June 6, 2013Inventor: Niles Ron
-
Publication number: 20130130980Abstract: The present invention provides an intraceptor that interacts with and decreases activity of with VEGF and/or a VEGFR for the treatment of angiogenesis-related conditions. The present invention further provides pharmaceutical compositions, and methods of use thereof, for the treatment and prevention of an angiogenesis-related condition using said intraceptors. The invention further provides for nucleic acids encoding said intraceptors.Type: ApplicationFiled: July 2, 2012Publication date: May 23, 2013Inventors: Balamurali Ambati, Nirbhai Singh, Shivan Amin
-
Publication number: 20130129621Abstract: Compounds comprising R-G-Cysteic Acid (i.e., R-G-NH—CH(CH2—SO3H)COOH or Arg-Gly-NH—CH(CH2—SO3H)COOH) and derivatives thereof, including pharmaceutically acceptable salts, hydrates, stereoisomers, multimers, cyclic forms, linear forms, drug-conjugates, pro-drugs and their derivatives. Also disclosed are methods for making and using such compounds including methods for inhibiting integrins including but not necessarily limited to ?5?1-Integrin, ?v?3-Integrin and ?v?5-Integrin, inhibiting cellular adhesion to RGD binding sites, preventing or treating viral or other microbial infections, inhibiting angiogenesis in tumors, retinal tissue or other tissues or delivering other diagnostic or therapeutic agents to RGD binding sites in human or animal subjects.Type: ApplicationFiled: May 9, 2012Publication date: May 23, 2013Applicant: ALLEGRO PHARMACEUTICALS, INC.Inventors: Michael John Mackel, John Y. Park, Hampar L. Karageozian, Vicken H. Karageozian
-
Patent number: 8444417Abstract: Methods for preventing, reversing, ameliorating or treating dental diseases, disorders or injuries are provided. In particular, methods for preventing, reversing, ameliorating or treating dental diseases of the gingival (gums) and bone are provided. Such methods utilize novel compositions including, but not limited to, extraembryonic cytokine-secreting cells (herein referred to as ECS cells), including, but not limited to, Amnion-derived Multipotent Progenitor cells (herein referred to as AMP cells) and conditioned media derived therefrom (herein referred to as Amnion-derived Cellular Cytokine Solution or ACCS), and Physiologic Cytokine Solution (herein referred to as PCS), each alone or in combination with each other and/or other agents.Type: GrantFiled: December 14, 2011Date of Patent: May 21, 2013Assignee: Stemnion, Inc.Inventors: William J. Golden, Randall G. Rupp
-
Patent number: 8444957Abstract: The present invention provide purified Flt4 receptor tyrosine kinase polypeptides and fragments thereof, polynucleotides encoding such polypeptides, antibodies that specifically bind such polypeptides, and uses therefor.Type: GrantFiled: February 17, 2010Date of Patent: May 21, 2013Assignee: Vegenics Pty LimitedInventors: Kari Alitalo, Arja Kaipainen, Rejia Valtola, Lolla Jussila
-
Publication number: 20130110132Abstract: Described herein are conditioned medium and processed conditioned medium, each of which comprises secreted stem cell factors; compositions containing conditioned medium and/or processed conditioned medium and a delivery polymer. The conditioned medium, processed conditioned medium and compositions may be used to promote blood vessel growth and healing of injured tissues.Type: ApplicationFiled: April 5, 2011Publication date: May 2, 2013Applicant: MedStar Health Research Institute, Inc.Inventors: Stephen E. Epstein, Mary Susan Burnett, Amir Najafi
-
Publication number: 20130108683Abstract: The present invention provides compositions and methods for treating deep partial thickness or full thickness wounds or injuries. The present invention also provides compositions and methods for promoting healing and regeneration of impaired or damaged tissue at a site of such partial thickness or full thickness wounds or injuries, as well as promoting vascularization and angiogenesis in regenerating and/or supportive tissue at such sites.Type: ApplicationFiled: October 24, 2012Publication date: May 2, 2013Applicant: BIOMIMETIC THERAPEUTICS, INC.Inventor: BioMimetic Therapeutics, Inc.
-
Publication number: 20130108670Abstract: The present invention provides compositions and methods for treating full thickness burn injuries. The present invention provides compositions and methods for promoting healing and regeneration of impaired or damaged tissue at a site of such a full thickness burn injury, as well as promoting vascularization and angiogenesis in regenerating tissue at such sites.Type: ApplicationFiled: October 24, 2012Publication date: May 2, 2013Applicant: BIOMIMETIC THERAPEUTICS, INC.Inventor: BioMimetic Therapeutics, Inc.
-
Publication number: 20130102531Abstract: Slow vascularization of functional blood limits the transplantation of tissue constructs and the recovery of ischemic and wounded tissues. Blood vessel ingrowth into polysaccharide-based hydrogel scaffolds remains a challenge. A synergistic effect of multiple angiogenic GFs was established; the co-encapsulation of VEGF plus other growth factors induced more and larger blood vessels than any individual GF, while the combination of all GFs dramatically increased the size and number of newly formed functional vessels. Rapid, efficient, and functional neovascularization may be achieved.Type: ApplicationFiled: June 30, 2011Publication date: April 25, 2013Applicant: The John Hopkins UniversityInventors: Sharon Gerecht, Guoming Sun, Yu-I Shen
-
Patent number: 8426357Abstract: The present invention is directed to a multimeric agent and a multimeric conjugate formed from this multimeric agent and a biologically active agent. Said multimeric conjugates have a longer life time in vivo and an increased avidity compared to the unmodified biologically agent. The present invention is further directed to a pharmaceutical or diagnostic composition containing said conjugate as well as to a method of its production. The invention additionally provides the use of said conjugates for the detection, determination, separation and/or isolation of a specific binding partner and for the diagnosis, prophylaxis and treatment of diseases in which the specific binding partner is directly or indirectly involved.Type: GrantFiled: February 11, 2008Date of Patent: April 23, 2013Assignees: celares GmbH, Scil Proteins GmbHInventors: Ralf Kraehmer, Frank Leenders, Erik Fiedler, Thomas Hey, Ulrike Fiedler, Markus Fiedler
-
Publication number: 20130095062Abstract: The present invention relates to novel expression cassettes and vectors for efficiently producing authentic recombinant human proteins from stable cultures of novel human cell lines, the authentic recombinant proteins produced therefrom, and antibodies raised against those authentic recombinant proteins.Type: ApplicationFiled: July 18, 2012Publication date: April 18, 2013Inventors: Ridong Chen, Soon Seog Jeong, Hui Feng
-
Publication number: 20130095060Abstract: The present invention relates to a pharmaceutical composition for promoting arteriogenesis, and preparation method and applications of the same, wherein said pharmaceutical composition comprises an effective amount of a drug, and a peptide hydrogel, and it forms a microenvironment for autologous cell recruitment and tissue regeneration.Type: ApplicationFiled: April 10, 2012Publication date: April 18, 2013Applicant: National Cheng Kung UniversityInventors: PATRICK C.H. HSIEH, YI-DONG LIN
-
Publication number: 20130078260Abstract: The present invention provides a compound which targets the VEGF and/or HIF pathways for use in the treatment and/or prevention of otitis media in a subject. The invention also provides a pharmaceutical composition comprising such a compound and a method for treating and/or preventing otitis media in a subject which comprises the step of administering such a compound or pharmaceutical composition to the subject.Type: ApplicationFiled: March 18, 2011Publication date: March 28, 2013Applicant: MEDICAL RESEARCH COUNCILInventors: Michael T. Cheeseman, Steve D.M. Brown
-
Patent number: 8404638Abstract: Formulations of a vascular endothelial growth factor (VEGF)-specific fusion protein antagonist are provided including a pre-lyophilized formulation, a reconstituted lyophilized formulation, and a stable liquid formulation. Preferably, the fusion protein has the sequence of SEQ ID NO:4.Type: GrantFiled: January 4, 2012Date of Patent: March 26, 2013Assignee: Regeneron Pharmaceuticals, Inc.Inventors: Daniel Dix, Kelly Frye, Susan Kautz
-
Publication number: 20130071443Abstract: Heparan sulphate HS7 is disclosed, together with the use of HS7 in the growth and/or development and/or regeneration of tissue.Type: ApplicationFiled: September 14, 2012Publication date: March 21, 2013Applicant: AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCHInventors: Simon Cool, Victor Nurcombe
-
Publication number: 20130071372Abstract: Metallo-proteins including but not limited to lactoferrin (LF), transferrin (TF) and ovotransferrin (OTF) (all members of transferrin family), ceruloplasmin (CP) and metallo-thionein (MT) were found to stabilize and enhance the bio-functional activity of tocotrienol (T3), T3 mixtures or derivates. The synergism between MP and T3 also promote the intestinal transfer and the ultimate bio-availability of T3 and T3-derivatives for physiological functions. Such functional synergism includes hypocholesterolemic, anti-thrombotic, antioxidant, anti-athermogenic, anti-inflammatory and immuno-regulatory activities of T3 agents. Addition of a non-protein-type metal chelator provided further improvement in the action of the bio-functional activity of T3. These T3 compositions are useful as pharmaceuticals, in cosmetics, in foods and as nutritional supplements.Type: ApplicationFiled: November 9, 2012Publication date: March 21, 2013Applicant: Naidu LPInventor: Naidu LP
-
Publication number: 20130071457Abstract: The invention is directed to a wound healing device. Such wound healing device utilizes novel wound healing compositions embedded onto or into a natural plant-derived cloth-based matrix.Type: ApplicationFiled: November 13, 2012Publication date: March 21, 2013Applicant: STEMNION, INC.Inventor: STEMNION, INC.
-
Publication number: 20130064886Abstract: Methods and systems are provided for making a drug microtablet. The method includes loading a lyophilization capillary channel with a liquid drug solution; lyophilizing the liquid drug solution in the lyophilization capillary channel to produce a lyophilized drug formulation; compressing the lyophilized drug formulation in the lyophilization capillary channel, or in a compression capillary channel, to form a microtablet; and ejecting the microtablet from the lyophilization capillary channel or compression capillary channel. The methods and systems may provide drug microtablets having improved content uniformity and reduced weight variability.Type: ApplicationFiled: November 8, 2012Publication date: March 14, 2013Applicant: On Demand Therapeutics, Inc.Inventor: On Demand Therapeutics, Inc.
-
Publication number: 20130065829Abstract: The present invention provides peptides and supported peptides for treating proliferative diseases. In particularly preferred embodiments, the present invention provides peptides and supported peptides for treating diseases of the skin, such as rosacea. In some particularly preferred embodiments, the supported peptides of the present invention are anti-VEGF peptides. In alternative particularly preferred embodiments, the anti-VEGF peptides are expressed on a scaffold protein. In some most preferred embodiments, the scaffold protein is BBI.Type: ApplicationFiled: September 10, 2012Publication date: March 14, 2013Applicant: Danisco US Inc.Inventors: Anthony G. Day, David A. Estell, Christopher J. Murray, Scott D. Power
-
Publication number: 20130058926Abstract: A method of alleviating and/or preventing skin reddening for a subject in need thereof by means of inhibiting angiogenesis at the site of the reddened skin, is provided.Type: ApplicationFiled: August 29, 2012Publication date: March 7, 2013Inventors: Kentaro Kajiya, Mika Sawane, Yuzo Yoshida, Katsujiro Sato
-
Patent number: 8388976Abstract: A polypeptide inhibiting binding between a vascular endothelial growth factor and a vascular endothelial growth factor receptor, a fusion protein including the same, and a method of preparing the fusion protein are disclosed.Type: GrantFiled: August 17, 2012Date of Patent: March 5, 2013Assignee: Samsung Electronics Co., Ltd.Inventors: A-yeon Cho, Min-kyung Kim, Brian Hosung Min, Jong-sang Ryu
-
Patent number: 8383788Abstract: A nucleotide molecule encoding a protein encoded by a Fos regulated gene or a fragment thereof, wherein said protein or fragment thereof is encoded by any one of the nucleotide sequences shown in FIG. 1 or 2 or a fragment thereof, including allelic variants and species variants of the nucleotide sequences.Type: GrantFiled: May 7, 2002Date of Patent: February 26, 2013Assignee: Vegenics Pty LimitedInventor: Salvatore Oliviero
-
Publication number: 20130045918Abstract: The present invention relates to a method of treating chronic wounds using calreticulin. In particular, the invention relates to the treatment of chronic diabetic wounds using topical application of calreticulin to a patient in need of such treatment.Type: ApplicationFiled: February 6, 2012Publication date: February 21, 2013Applicants: CALREGEN INC., NEW YORK UNIVERSITYInventors: Leslie I. Gold, Marek Michalak
-
Publication number: 20130040880Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: October 17, 2012Publication date: February 14, 2013Applicant: Stemnion, Inc.Inventors: Vivienne S. Marshall, Catherine J. Trumpower, Charlotte A. Smith, George L. Sing, Linda O. Palladino
-
Patent number: 8367609Abstract: This application features methods of treating (e.g., reducing, ameliorating, or preventing) skin damage (e.g., induced by UVB) by decreasing the level or activity of VEGF-A, e.g., in the skin, of a subject.Type: GrantFiled: January 18, 2007Date of Patent: February 5, 2013Assignee: The General Hospital CorporationInventors: Michael Detmar, Kentaro Kajiya
-
Publication number: 20130029909Abstract: Provided are methods relating to compositions that include a CDP-topoisomerase inhibitor, e.g., a CDP-camptothecin or camptothecin derivative conjugate, e.g., CRLX101.Type: ApplicationFiled: May 23, 2012Publication date: January 31, 2013Inventor: John Ryan
-
Publication number: 20130028984Abstract: Tissue fillers derived from decellularized tissues are provided. The tissue fillers can include acellular tissue matrices that have reduced inflammatory responses when implanted in a body. Also provided are methods of making and therapeutic uses for the tissue fillers.Type: ApplicationFiled: July 27, 2012Publication date: January 31, 2013Inventors: Hui Xu, Wenquan Sun, Hua Wan, Rick Owens
-
Publication number: 20130028911Abstract: The present invention provides human vascular endothelial cell growth factor (hVEGF) antagonists, including monoclonal antibodies, hVEGF receptors, and hVEGF variants that are useful for the treatment of age-related macular degeneration, and other diseases and disorders characterized by undesirable or excessive neovascularization.Type: ApplicationFiled: February 24, 2012Publication date: January 31, 2013Applicant: Genentech, Inc.Inventors: Napoleone Ferrara, Kyung Jin Kim
-
Publication number: 20130022551Abstract: Provided herein are novel compositions comprising DEspR-specific antagonists and agonists, and methods of their use in a variety of therapeutic applications. The compositions comprising the DEspR-specific anatgonists and agonists described herein are useful in therapeutic, diagnostic and imaging methods, such as DEspR-targeted molecular imaging of angiogenesis, and for companion diagnostic and/or in vivo-non invasive imaging and/or assessments.Type: ApplicationFiled: January 23, 2012Publication date: January 24, 2013Applicant: TRUSTEES OF BOSTON UNIVERSITYInventors: Nelson Ruiz-Opazo, Victoria L.M. Herrera
-
Patent number: 8357388Abstract: The present invention relates to novel drug depot implant designs for optimal delivery of therapeutic agents to subjects. The invention provides a method for alleviating pain associated with neuromuscular or skeletal injury or inflammation by targeted delivery of one or more therapeutic agents to inhibit the inflammatory response which ultimately causes acute or chronic pain. Controlled and directed delivery can be provided by drug depot implants, comprising therapeutic agents, specifically designed to deliver the therapeutic agent to the desired location by facilitating their implantation, minimizing their migration from the desired tissue location, and without disrupting normal joint and soft tissue movement.Type: GrantFiled: March 3, 2010Date of Patent: January 22, 2013Assignee: Warsaw Orthopedic, Inc.Inventor: William F. McKay
-
Publication number: 20130017996Abstract: The present invention relates to novel muteins derived from human tear lipocalin. The invention also refers to a corresponding nucleic acid molecule encoding such a mutein and to a method for its generation. The invention further refers to a method for producing such a mutein. Finally, the invention is directed to a pharmaceutical composition comprising such a lipocalin mutein as well as to various uses of the mutein.Type: ApplicationFiled: September 14, 2012Publication date: January 17, 2013Inventors: Kristian Jensen, Martin Huelsmeyer, Steffen Schlehuber, Andreas Hohlbaum, Arne Skerra, Eric Boudreau, Richard Jones, Ian Kimber, Rebecca Dearman
-
Publication number: 20130017169Abstract: Multimeric protein structures are disclosed herein, as well a process for preparing same, and methods employing same for treating various diseases or disorders. The multimeric protein structures comprise at least two monomers of a therapeutic protein, including a TNF-alpha, a luteinizing hormone, an immunoglobin, a TNF-alpha receptor, a CTLA-4, a urate oxidase, a VEGF, a PDGF, a VEGF receptor, a PDGF receptor, an interleukin-17, and/or fragments thereof, the monomers being covalently linked to one another via a linking moiety. The multimeric protein structures exhibit improved performance as compared to the corresponding native proteins, including a longer lasting activity in vivo.Type: ApplicationFiled: March 2, 2011Publication date: January 17, 2013Applicant: PROTALIX LTD.Inventors: Ilya Ruderfer, Orit Shilovittzky, Avidor Shulman, Joseph Shaaltiel, Tehila Ben-Moshe, Talia Shekhter, Yaniv Azulay
-
Publication number: 20130012435Abstract: The present invention relates to multivalent polypeptides comprising at least two fibronectin scaffold domains connected via a polypeptide linker. The invention also relates to multivalent polypeptides for use in diagnostic, research and therapeutic applications. The invention further relates to cells comprising such proteins, polynucleotide encoding such proteins or fragments thereof, and to vectors comprising the polynucleotides encoding the innovative proteins.Type: ApplicationFiled: June 26, 2012Publication date: January 10, 2013Applicant: Bristol-Myers Squibb CompanyInventors: Ray Camphausen, Eric Furfine, Irvith M. Carvajal, H. Nicholas Marsh, Marco Gottardis, Joan Carboni, Ricardo Attar
-
Patent number: 8343479Abstract: Methods, compositions, and kits for repairing damaged myocardium and/or myocardial cells including the administration of stem cells, such as adult stem cells, optionally with cytokines are disclosed and claimed.Type: GrantFiled: December 20, 2007Date of Patent: January 1, 2013Assignee: New York Medical CollegeInventors: Piero Anversa, Donald Orlic
-
Publication number: 20120328557Abstract: Described herein is a cell tissue gel cross-linked with a cross-linking agent, and a quenching agent bound to a reactive group of the cross-linking agent.Type: ApplicationFiled: June 23, 2011Publication date: December 27, 2012Applicants: Excel Med, LLC, National Cheng Kung UniversityInventor: Lynn L.H. Huang
-
Publication number: 20120321597Abstract: Connective tissue regenerative compositions and methods of repairing and regenerating connective tissue using such compositions are provided. The compositions generally comprise a bioactive hydrogel matrix comprising a polypeptide, such as gelatin, and a long chain carbohydrate, such as dextran. The hydrogel matrix may further include polar amino acids, as well as additional beneficial additives. Advantageously, the compositions include further components, such as osteoinductive or osteoconductive materials, medicaments, stem or progenitor cells, and three-dimensional structural frameworks. The compositions are useful for regenerating connective tissue, and can be administered to an area having injury to, or a loss of, connective tissue, such as bone, cartilage, tendon, and ligament.Type: ApplicationFiled: August 31, 2012Publication date: December 20, 2012Inventors: Ronald Stewart Hill, Richard Chris Klann, Francis V. Lamberti
-
Publication number: 20120321591Abstract: The present invention provides various uses of VEGF binding peptides, including methods to treat disorders associated with abnormal angiogenesis.Type: ApplicationFiled: August 27, 2012Publication date: December 20, 2012Inventors: Venkata Ramana Doppalapudi, Jing-Yu Lai, Bin Liu, Dingguo Liu, Joel Desharnais, Abhijit Suresh Bhat, Yanwen Fu, Bryan Douglas Oates, Gang Chen, Curt William Bradshaw
-
Publication number: 20120322731Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: ApplicationFiled: August 28, 2012Publication date: December 20, 2012Applicant: STEMNION, INC.Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower, George L. Sing, Linda O. Palladino
-
Publication number: 20120323310Abstract: The present invention is directed to a drug eluting stent system, including: a stent; a tocopherol agent coupled to the stent; wherein the stent is adapted to elute the tocopherol agent into a surrounding lumenal wall tissue when implanted along the lumen within a body of a patient.Type: ApplicationFiled: January 24, 2012Publication date: December 20, 2012Applicant: CELONOVA BIOSCIENCES, INC.Inventors: James W. Larrick, James C. Peacock, III
-
Publication number: 20120316110Abstract: A therapeutic composition for treatment of a body tissue which includes an aqueous solution of a cross-linked polymer being capable of: (i) maintaining a liquid state in storage at room temperature for at least 24 hours; and (ii) assuming a gel state following deposition within the body tissue. The therapeutic composition can be effectively administered into a damaged body tissue via injection or catheterization, thereby treating the damaged body tissue.Type: ApplicationFiled: March 26, 2012Publication date: December 13, 2012Applicant: Ben-Gurion University of the NegevInventors: Smadar Cohen, Jonathan Leor
-
Publication number: 20120308554Abstract: The present invention relates to methods for modulating, i.e. increasing or decreasing, the length and/or the complexity of the dendrites of a neuronal cell by influencing the amount of vascular endothelial growth factor D (VEGFD)-related signaling. The present invention further relates to methods for treating age- and/or disease-related cognitive dysfunctions, or for impairing the memory of a subject. Finally, the present invention relates to recombinant VEGFD (rVEGFD) for use in the treatment of age- and/or disease-related cognitive dysfunctions.Type: ApplicationFiled: June 1, 2011Publication date: December 6, 2012Applicant: UNIVERSITAT HEIDELBERGInventors: Hilmar Bading, Daniela Mauceri
-
Publication number: 20120301538Abstract: The invention relates to a human or veterinary pharmaceutical composition (B) for the stimulation of stem cells, comprising at least two stem-cells-stimulating-agents and at least one pharmaceutically acceptable excipient.Type: ApplicationFiled: May 31, 2012Publication date: November 29, 2012Inventors: Roland GORDON-BERESFORD, Vinciane Gaussin, Jean-Pierre Latere Dwan'isa, Christian Homsy
-
Patent number: 8318672Abstract: The invention is directed to novel cellular factor-containing solution compositions (referred to herein as “CFS” compositions), including novel sustained-release cellular factor-containing solution compositions (referred to herein as “SR-CFS” compositions), methods of making such novel compositions and uses thereof.Type: GrantFiled: April 10, 2012Date of Patent: November 27, 2012Assignee: Stemnion, Inc.Inventors: Vivienne S. Marshall, Charlotte A. Smith, Catherine J. Trumpower
-
Patent number: 8318197Abstract: The invention is directed to a novel wound healing device. In particular, the invention is directed to a novel wound healing device comprising a suture or knitted mesh that has adsorbed onto it novel cellular factor-containing compositions (referred to herein as CFC), including Amnion-derived Cellular Cytokine Solution (referred to herein as ACCS) or Physiologic Cytokine Solutions (herein referred to as PCS), as well as methods of making and uses thereof.Type: GrantFiled: January 17, 2012Date of Patent: November 27, 2012Assignee: Stemnion, Inc.Inventors: David L. Steed, Randall G. Rupp, Howard C. Wessel